BioSante Bio-E-Gel Transdermal Estradiol Is Firm’s First NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
BioSante is seeking approval of Bio-E-Gel for treatment of moderate-to-severe hot flashes in menopausal women.
You may also be interested in...
BioSante To Launch Hot Flash Drug Elestrin in 2007
Following FDA approval, the product is being positioned as the lowest dose of estradiol for moderate-to-severe hot flashes.
BioSante To Launch Hot Flash Drug Elestrin in 2007
Following FDA approval, the product is being positioned as the lowest dose of estradiol for moderate-to-severe hot flashes.
BioSante Expects Estradiol, Testosterone Gel Filings In 2004; Marketing Will Ride Solvay Coattails
Company aims to capture 10%-20% of the testosterone gel market with Bio-T-Gel. Female sexual dysfunction will be next frontier for BioSante gels, with Procter & Gamble as trailblazer in FSD market, BioSante CEO says.